ArticleNature immunology2024
Attenuated effector T cells are linked to control of chronic HBV infection.
Abstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions.Annals of medicine · 2026Review
- A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection.Alimentary pharmacology & therapeutics · 2026Article
- ANKRD11 deficiency reprograms CD8Nature immunology · 2026Article
- Review
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Persistent loss of intrahepatic IFN-γ in HBV is linked to selective impairment of liver-resident CXCR6+NK cells despite long-term NUC therapy.JHEP reports : innovation in hepatology · 2026Article
- New insights into progenitor exhausted T cell populations.Nature reviews. Immunology · 2026Article
- Association between changes in HBsAb levels and hepatic adverse events after HBsAg clearance in non-cirrhotic chronic hepatitis B patients.BMC infectious diseases · 2026Observational
- Engineering a dual-antigen mRNA vaccine to restore immune control in chronic hepatitis B.Nature communications · 2026Article
- An integrative transcriptomic analysis for prognosis and tumor microenvironment in HBV/HCV-associated hepatocellular carcinoma.Molecular therapy. Oncology · 2026Article
- Compensatory relationships determine the impact of TGF-β on the humoral immune response to hepatitis B surface antigen.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- T cell adaptation in chronic infections and tumors.Cellular & molecular immunology · 2026Review
- Regulation of immune tolerance in hepatocellular carcinoma by liver diseases: a review.Infectious agents and cancer · 2026Review
- Clonal amplification of peripheral CD4+ and CD8+ T cells is associated with clinical response to checkpoint blockade in chronic hepatitis B.ImmunoHorizons · 2026Article
- T-Cell Profiles in HBV Functional Cure and People Living With HIV: Known Knowns, Known Unknowns, and Unknown Unknowns.Current HIV/AIDS reports · 2026Review
- Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 logJournal of clinical medicine · 2026Article
- Transcriptional and functional HBV-specific CD8 T cell changes from disease to functional cure in HBeAg-negative chronic hepatitis B.JHEP reports : innovation in hepatology · 2026Article
- Regulators of CD8Nature reviews. Immunology · 2026Review
- The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B.Frontiers in immunology · 2026Review
- From mechanisms to practice: risk management and multidisciplinary decision-making for systemic treatment-related liver injury in HBV-associated hepatocellular carcinoma.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Kathrin Heim *Department of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.
Sagar *Department of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-8657-4704
Özlem SogukpinarDepartment of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.
Sian Llewellyn-LaceyDivision of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK.
David A PriceDivision of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK.ORCID http://orcid.org/0000-0001-9416-2737
Florian EmmerichFaculty of Medicine, University of Freiburg, Freiburg, Germany.
Anke R M KraftDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0002-9666-0753
Markus CornbergDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Sophie KielbassaDepartment of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.
Percy KnolleInstitute of Molecular Immunology, School of Medicine, Technical University of Munich (TUM), Munich, Germany.ORCID http://orcid.org/0000-0003-2983-0414
Dirk WohlleberInstitute of Molecular Immunology, School of Medicine, Technical University of Munich (TUM), Munich, Germany.ORCID http://orcid.org/0000-0003-3861-5150
Bertram BengschDepartment of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-2552-740X
Tobias BoettlerDepartment of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-1195-055X
Christoph Neumann-HaefelinDepartment of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-7351-1387
Robert ThimmeDepartment of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany. robert.thimme@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0003-1417-4135
Maike HofmannDepartment of Medicine II, Medical Center - University of Freiburg, Freiburg, Germany. maike.hofmann@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0001-8410-8833
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) CRC 1160 project no. 256073931Deutsche Forschungsgemeinschaft (German Research Foundation) CRC 1479 project no. 441891347Deutsche Forschungsgemeinschaft (German Research Foundation) TRR 179 project no. 272983813
Abstract
Hepatitis B virus (HBV)-specific CD8
Indexed as
CD8-Positive T-LymphocytesHepatitis B, ChronicHepatitis B virusAdultCell DifferentiationFemaleHumansMaleMiddle AgedSignal TransductionTransforming Growth Factor betaVirus ReplicationTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.